DC-806, an oral IL-17A inhibitor:

Proof-of-concept in adults with mild-to-moderate psoriasis

Warren RB[1], Hunter HJA[1], Papp KA[2], Gordon KB[3], Huang KC[4], Enejosa JV[4], Tang MT[4], Raha D[4], Fatheree P[4], Jacobsen JR[4], Lu TT[4]

[1] Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR BRC, University of Manchester, Manchester UK
[2] Kim Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada
[3] Department of Dermatology, Medical College of Wisconsin, Milwaukee
[4] DICE Therapeutics, South San Francisco, CA

Disclosures

RB Warren: AbbVie, Almirall, Arena, Aristea, Amgen, Astellas, Avillion, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DICE, Eli Lilly, GSK, Janssen, Lilly, Leo, Medac, Novartis, Pfizer, Sanofi, Sun Pharma, UCB and UNION.

HJA Hunter: AbbVie, Almirall, DICE Therapeutics, Eli Lilly, Janssen, La Roche-Posey, Leo, Pfizer, Janssen, Merck Serono, Novartis Regeneron, Sanofi Genzyme, UCB, UNION Therapeutics

KA Papp: AbbVie, Acelyrin, Akros, Amgen, Anacor, Aralez Pharmaceuticals, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Celltrion, Coherus, Dermavant, Dermira, DICE Therapeutics, Dow Pharma, Eli Lilly, Evelo, Forbion, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Meiji Seika Pharma, Merck (MSD), Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, Xencor

KB Gordon: AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant, Incyte, Janssen, Lilly, Novartis, MoonLake, UCB, Union, DICE Therapeutics, Protagonist Therapeutics

KC Huang: Employee of DICE Therapeutics

JV Enejosa: Employee of DICE Therapeutics

MT Tang: Employee of DICE Therapeutics

D Raha: Employee of DICE Therapeutics

P Fatheree: Employee of DICE Therapeutics

JR Jacobsen: Employee of DICE Therapeutics

TT Lu: Employee of DICE Therapeutics

DC-806: blocking the *same step* as the antibodies via allosteric binding event

IL-17AA + ANTIBODY

IL-17 AA + RECEPTOR

IL-17 AA + DC-806











PRO-INFLAMMATORY SIGNAL

Phase 1 SAD/MAD in Healthy Participants and P1c in Psoriasis Patients

Safe and well tolerated in Healthy Participants



Key Objective of P1c

- Evaluate the safety, tolerability, and PK and explore preliminary clinical activity and pharmacodynamics of DC-806 in patients with psoriasis

Baseline demographics and disease characteristics

Mild – moderate patient population enrolled

	DC-806 200mg BID N=13	DC-806 800mg BID N=8	Placebo N=11
Age in years, mean (SD)	41.8 (12.8)	47.0 (13.3)	38.5 (10.9)
Male, n (%)	9 (69.2)	8 (100)	9 (81.8)
Race, n (%)			
White	10 (76.9)	8 (100)	11 (100)
Asian	3 (23.1)	0	0
Weight in kg, mean (SD)	88.9 (17.0)	82.2 (15.0)	88.8 (18.3)
PASI Score, mean (SD)	6.08 (3.0)	6.74 (2.2)	7.15 (1.6)
Percent BSA involvement %, mean (SD)	6.98 (4.5)	8.49 (7.0)	8.52 (4.3)

BID = twice daily | PASI = Psoriasis Area and Severity Index | BSA = Body surface area